Mayne Pharma and Sandoz announced a partnership for Mayne Pharma to provide Sandoz exclusive rights to promote, sell and distribute Mayne Pharma® Oxycodone IR 5 mg and Metaraminol MYX® 10 mg / 1 ml Solution for Injection Ampoules 5 in Australia. General Manager for Mayne Pharma, Grant Swart, commented: “Our relationship with Sandoz is aligned to our longer-term growth strategy where we will look to establish mutually beneficial relationships with our partners. Oxycodone and Metaraminol are both well-established products in the Australian market and this new agreement will ensure increased availability for patients. We look forward to a successful long-term partnership with Sandoz to provide greater access to medicines for patients.”
Exciting news for Mayne Pharma and Sandoz Australia & New Zealand with this partnership! Huge shout out to our team for all their hard work and support to get this partnership agreement signed. Grant Swart Trudy Boyce #maynepharma #partnership
Well done team!
Executive General Manager | Business Transformation & Turnaround specialist | Full P&L management | Revenue growth | Operational Excellence | Sourcing & Procurement
2moWell done to our commercial team for getting this over the line.